Novo Nordisk Gets Rare Sell Rating as Pipeline and Growth Concerns Mount
Analysts cite ziltivekimab’s trial miss, modest Medicare upside and patent risks.
/ 1648 items
#XY↓
FDA Approves First Targeted RAS Drug for Metastatic Pancreatic Cancer
The FDA approved Revolution’s Rasonque, the first RAS-targeted daily pill for metastatic pancreatic cancer. It doubled median survival to 13.2 months, compared with 6.7 months with chemotherapy.
Cardiol Therapeutics: B. Riley Sees 450% Upside as Phase 3 MAVERIC Trial Nears Completion
B. Riley initiates Cardiol Therapeutics at Buy with an $11 target, citing a de-risked Phase 3 MAVERIC trial and strong cash runway.
Boston Scientific Faces Weeks-Long Disruption From Cyberattack as Analysts Eye Q3 Impact
Boston Scientific reports a cyberattack detected August 25, 2026, disrupting systems, delaying product shipments worldwide. Full scope still unknown.
SK Biopharmaceuticals Licenses Biohaven’s Kv7 Platform in Deal Worth Up to $795 Million
SK Biopharm gains exclusive worldwide rights to Biohaven’s opakalim and Kv7 platform in a deal worth up to $795M, with a possible 2029 U.S. launch.
Phase 2 Data Support TL1A Inhibition in RA, but Spyre Opts Against Monotherapy Priority
Spyre’s RA drug showed benefits and good safety, but results weren’t strong enough to justify developing it as a stand-alone treatment.